Skip to main content

Table 5 Interventions against HIV/AIDS and their associated coverage levels, total costs, yearly costs, yearly infections averted, yearly DALYS averted and sorted by average cost effectiveness

From: Determining a cost effective intervention response to HIV/AIDS in Peru

Intervention Coverage level (%) Total costs ($ Millions) 2008-2013 Yearly costs ($ Millions) Total infections averted (2008-2013) Yearly infections averted Yearly DALYS averted Average cost effectiveness - $/DALY averted (range*)
FSW 50 0.6 0.1 1,970 394 10,118 55 (2 - 124)
FSW 95 1.0 0.2 3,730 746 19,157 55 (1 - 105)
FSW 80 0.9 0.1 3,130 626 16,076 55 (2 - 116)
Blood safety 50 5.3 0.9 13,050 2,610 67,025 79 (41 - 79)
Blood safety 80 8.5 1.4 20,570 4,114 105,648 80 (43 - 80)
Blood safety 95 10.1 1.7 24,260 4,852 124,599 81 (43 - 91)
VCT 95 8.2 1.4 13,870 2,774 71,236 116 (18 - 116)
VCT 50 4.4 0.7 7,300 1,460 37,493 118 (18 - 118)
VCT 80 7.1 1.2 11,670 2,334 59,937 118 (18 - 118)
Youth: in-school 50 13.7 2.3 21,760 4,352 131,126 104 (12 - 177)
Youth: in-school 80 22.0 3.7 22,760 4,552 137,152 161 (19 - 270)
Youth: in-school 95 26.2 4.4 23,020 4,604 138,719 189 (12 - 630)
mass media 50 11.3 1.9 8,930 1,786 45,864 246 (89 - 253)
Condoms 95 61.0 10.2 23,740 4,748 121,929 500 (64 - 500)
Condoms 80 51.3 8.6 19,890 3,978 102,155 503 (62 - 503)
Condoms 50 32.1 5.3 12,430 2,486 63,840 503 (58 - 503)
STI treatment 50 25.1 4.2 6,600 1,320 33,898 739 (200 - 1021)
STI treatment 80 40.1 6.7 10,290 2,058 52,849 759 (199 - 1045)
STI treatment 95 47.6 7.9 12,080 2,416 62,043 767 (200 - 1055)
MSM 50 75.0 12.5 11,090 2,218 56,958 1,317 (354 - 1317)
MSM 80 120.0 20.0 17,570 3,514 90,240 1,330 (351 - 1330)
MSM 95 142.5 23.8 20,770 4,154 106,675 1,336 (350 - 1336)
HAART        
   Comprehensive 95 37.7 6.3 - - 18917 1995
   Intermediate 95 37.7 6.3 - - 16412 2297
   Basic 95 33.6 5.6 - - 13999 2403
PMTCT 80 246.4 41.1 10,460 2092 41,557 5,928 (2313 - 5.928)
  1. *Ranges based upon sensitivity analysis whereby the model was run using randomly generated values for the behavioural and biological parameters which were varied so that HIV prevalence rates did not deviate by greater than 50% from the baseline predictions.